2. Search Result
Search Result
Results for "

FER

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

1

Recombinant Proteins

1

Antibodies

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100579
    Ferrostatin-1
    Maximum Cited Publications
    762 Publications Verification

    FER-1

    		 Ferroptosis Fungal Cancer
    Ferrostatin-1 (Fer-1), a potent and selective ferroptosis inhibitor, suppresses Erastin-induced ferroptosis in HT-1080 cells (EC50=60 nM). Ferrostatin-1, a synthetic antioxidant, acts via a reductive mechanism to prevent damage to membrane lipids and thereby inhibits cell death. Ferrostatin-1 exhibits antifungal activity .
    Ferrostatin-1
  • HY-112097
    E260
    1 Publications Verification

    		 Others Cancer
    E260 is a Fer/FerT kinase inhibitor.
    E260
  • HY-116087
    SRS11-92

    		Ferroptosis Neurological Disease Cancer
    SRS11-92, a Ferrostatin-1 (Fer-1) analogue, is a potent ferroptosis inhibitor. SRS11-92 inhibits ferroptotic cell death induced by Erastin in HT-1080 human fibrosarcoma cells (EC50=6 nM) .
    SRS11-92
  • HY-128576
    DS21360717
    1 Publications Verification

    		 Others Cancer
    DS21360717 is a potent and orally active FER tyrosine kinase inhibitor, with an IC50 of 0.49 nM. Anti-cancer activity .
    DS21360717
  • HY-122844
    Ifebemtinib
    1 Publications Verification

    BI-853520; IN-10018

    		 FAK Cancer
    Ifebemtinib (BI 853520) is an orally active and potent focal adhesion kinase (FAK) inhibitor (recombinant FAK IC50=1?nM). Ifebemtinib shows anti-proliferative activity against cancer cells. Ifebemtinib inhibits FER Kinase and FES Kinase with IC50s of 900?nM and 1040?nM, respectively .
    Ifebemtinib
  • HY-136194
    TL13-22

    		Anaplastic lymphoma kinase (ALK) Cancer
    TL13-22 is a negative control for TL13-12 (HY-122582) and a potent ALK inhibitor with an IC50 of 0.54 nM. TL13-22 does not degrade ALK in cells .
    TL13-22
  • HY-156066
    Ferrostatin-1 diyne

    FER-1 diyne

    		 Ferroptosis Cancer
    Ferrostatin-1 diyne (Fer-1 diyne) (compound 2) is a ferroptosis inhibitor that accumulates in lysosomes, mitochondria, and endoplasmic reticulum in cells, but its inhibition of ferroptosis is not dependent on the activity of lysosomes and mitochondria.
    Ferrostatin-1 diyne
  • HY-RS04862
    FER Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    FER Human Pre-designed siRNA Set A contains three designed siRNAs for FER gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    FER Human Pre-designed siRNA Set A
    FER Human Pre-designed siRNA Set A
  • HY-RS04863
    FER1L6 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    FER1L6 Human Pre-designed siRNA Set A contains three designed siRNAs for FER1L6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    FER1L6 Human Pre-designed siRNA Set A
    FER1L6 Human Pre-designed siRNA Set A
  • HY-161731
    DS08701581

    		Others Cancer
    DS08701581 is an inhibitor of FER tyrosine kinase with IC50. DS08701581 has anti-tumor activity and oral activity .
    DS08701581
  • HY-136195
    TL13-110

    		Anaplastic lymphoma kinase (ALK) Cancer
    TL13-110 is a negative control for TL13-112 (HY-123919) and a potent ALK inhibitor with an IC50 of 0.34 nM. TL13-110 does not degrade ALK in cells .
    TL13-110
  • HY-123919
    TL13-112
    1 Publications Verification

    		 PROTACs Anaplastic lymphoma kinase (ALK) Cancer
    TL13-112 is a potent and selective ALK-PROTAC degrader and inhibits ALK activity with an IC50 value of 0.14 nM. TL13-112 also prompts the degradation of additional kinases including Aurora A, FER, PTK2 and RPS6KA1 with IC50 values of 8550 nM, 42.4 nM, 25.4 nM, and 677 nM, respectively. TL13-112 is comprised of the conjugation of Ceritinib?(HY-15656) and the Cereblon ligand of Pomalidomide (HY-10984) .
    TL13-112
  • HY-122582
    TL13-12

    		PROTACs Anaplastic lymphoma kinase (ALK) Cancer
    TL13-12 is a potent and selective?ALK-PROTAC?degrader and inhibits?ALK?activity with an IC50 value of 0.69 nM. TL13-12 also prompts the degradation of additional kinases including Aurora A, FER, PTK2, and RPS6KA1 with IC50 values of 13.5 nM, 5.74 nM, 18.4 nM, and 65 nM, respectively. TL13-12 is comprised of the conjugation of TAE684 (HY-10192) and the Cereblon ligand of Pomalidomide (HY-10984) .
    TL13-12
  • HY-10338A
    Foretinib phosphate

    		c-Met/HGFR VEGFR Cancer
    Foretinib phosphate is an orally bioavailable small molecule with potential anti-tumor activity. Foretinib phosphate can selectively inhibit hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), thereby potentially inhibiting tumor angiogenesis, tumor cell proliferation and metastasis. Foretinib phosphate shows different anti-cancer activity from cabozantinib in lung cancer cells and has stronger inhibitory effects on targets such as MEK1/2, FER and AURKB .
    Foretinib phosphate
  • HY-148061
    DB1113

    		PROTACs Bcr-Abl CDK Salt-inducible Kinase (SIK) Cyclin G-associated Kinase (GAK) MAP4K MAPKAPK2 (MK2) Ferroptosis ULK LIM Kinase (LIMK) Others
    DB1113 (Example 24) is a bifunctional compound targeted protein degradation of kinases. DB1113 degrades ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2, and ULK1. DB1113 can be used for research of disease or disorder mediated by aberrant kinase activity .
    DB1113
  • HY-148063
    DB0614

    		PROTACs AAK1 Aurora Kinase CaMK CDK Ferroptosis Salt-inducible Kinase (SIK) LIM Kinase (LIMK) ULK Metabolic Disease
    DB0614 is a PROTAC based on Cereblon ligand, which is a selective and potent targeted protein degrader of NEK9 inhibitor. DB0614 can degrade ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2 and ULK1. DB0614 can be used for research of disease or disorder mediated by aberrant kinase activity .(Blue: Thalidomide-4-OH (HY-103596), Black: linker, Pink: FLT3-IN-17 (HY-148070))
    DB0614

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: